In the 1980s, after identifying the cDNA sequence and mRNA of proglucagon, two new glucagon-like peptides, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) (Bell et al., 1983
GHK-Cu is the copper(II)-binding tripeptide glycyl- L -histidyl- L -lysine, a naturally occurring sequence with high affinity for copper ions
Smaller or more delicate peptides may require use within two weeks
2 Scientific studies have shown connections between the use of GLP-1 drugs and an increased risk of gastrointestinal issues, 3 including gastroparesis
However, patients experiencing significant weight loss on GLP-1 therapy may require more frequent monitoring, with TSH rechecked 6-8 weeks after significant weight change or dose adjustment, then every 3-4 months during active weight loss
We've seen patients with seemingly great insurance get denied, while others with more basic plans get approved